TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05324020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication adherence eHealth intervention
Description: The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies).
Study: NCT05482633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: Treatment group will perform IMT every day for eight weeks. Initial load is going to be set as the 60% of maximal inspiratory pressure (PImax) and is going to be increased by %10 of the initial load every two weeks.
Study: NCT06309355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The intervention is Placebo on a range of body surface area for multiple topical administration
Study: NCT04998344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Description: Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated polio vaccine
Description: Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
Study: NCT04905563

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen-Hydrocodone
Description: Narcotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen and Ibuprofen
Description: Non-narcotic
Study: NCT05959252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Bivalirudin protocol with target aPTT 50-70 seconds
Study: NCT05470205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement (Sonazoid ultrasoud contrast agent)
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement (Sonazoid ultrasoud contrast agent)
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement (Sonazoid ultrasoud contrast agent)
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement (Sonazoid ultrasoud contrast agent)
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement (Definity ultrasoud contrast agent)
Description: Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
Study: NCT06346249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Therapy
Description: Ten Electrical Stimulation Therapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual Therapy consistin of soft tissue mobilization and release techniques over the neck and craniocervical regions. Ten sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapeutic
Description: The exercise therapeutic program consisting of neck movement control and stretching exercise. Ten sessions.
Study: NCT01101347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aneurysm-Embolization System
Study: NCT05058248

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pudendal block
Description: general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pudendal block
Description: general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco
Study: NCT06522685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation Soterix REMOTE 1x1 miniCT
Description: Soterix Medical REMOTE Neuromodulation is the only system with device, accessories, and software designed for deployed use. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation Soterix REMOTE 1x1 miniCT
Description: Soterix Medical REMOTE Neuromodulation is the only system with device, accessories, and software designed for deployed use. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.
Study: NCT05868733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Lower Dose (2×106 pfu)
Description: rVSV∆G-LASV-GPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Lower Dose (2×106 pfu)
Description: rVSV∆G-LASV-GPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Lower Dose (2×106 pfu)
Description: rVSV∆G-LASV-GPC
Study: NCT04663828

Intervention type: OTHER
Group type: OTHER
Intervention: Structured counseling
Description: Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder

Intervention type: OTHER
Group type: OTHER
Intervention: Structured counseling
Description: Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder

Intervention type: OTHER
Group type: OTHER
Intervention: Structured counseling
Description: Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder

Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing aids
Description: Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.

Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing aids
Description: Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.

Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing aids
Description: Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.

Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing aids
Description: Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
Study: NCT05868733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Lower Dose (2×106 pfu)
Description: rVSV∆G-LASV-GPC
Study: NCT04663828

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
Study: NCT05868733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Lower Dose (2×106 pfu)
Description: rVSV∆G-LASV-GPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Higher Dose (1×107 pfu)
Description: rVSV∆G-LASV-GPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Higher Dose (1×107 pfu)
Description: rVSV∆G-LASV-GPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Higher Dose (1×107 pfu)
Description: rVSV∆G-LASV-GPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Higher Dose (1×107 pfu)
Description: rVSV∆G-LASV-GPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1 Higher Dose (1×107 pfu)
Description: rVSV∆G-LASV-GPC
Study: NCT04663828

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups

Intervention type: OTHER
Group type: OTHER
Intervention: Sound therapy
Description: Several sounds and music are used for tinnitus disorder

Intervention type: OTHER
Group type: OTHER
Intervention: Sound therapy
Description: Several sounds and music are used for tinnitus disorder
Study: NCT05868733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04663828

Intervention type: OTHER
Group type: OTHER
Intervention: Sound therapy
Description: Several sounds and music are used for tinnitus disorder

Intervention type: OTHER
Group type: OTHER
Intervention: Sound therapy
Description: Several sounds and music are used for tinnitus disorder

Intervention type: OTHER
Group type: OTHER
Intervention: Sound therapy
Description: Several sounds and music are used for tinnitus disorder
Study: NCT06055491

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 or Saline injection at ipsilateral deltoid muscle
Description: study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 or Saline injection at ipsilateral deltoid muscle
Description: study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection
Study: NCT05868733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03895567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
Description: Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
Description: Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).
Study: NCT05793476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fotona Dynamis Er:YAG Laser System
Description: The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 15-21 days. She receives 3 sessions, in total. 5% Lidocaine cream is applied 30 minutes before each procedure. Each session consists of application of R11 handpiece to the episiotomy scar at Turbo3 Micro Short Pulse mode, with spot size of 2 mm, fluence of 9.5-10 j/cm2, frequency of 2 Hz and 4 pulses per point and 3 passes followed by PS03 handpiece at Basic Long Pulse mode, with spot size of 5 mm, energy of 800 mJ, frequency of 1.4 Hz and 4 pulses per point and 2 passes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fotona Dynamis Er:YAG Laser System with Sham handpiece
Description: The same procedure is applied above but with a sham handpiece and parameter presentations masked.
Study: NCT03895567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
Description: Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
Description: Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
Description: Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
Description: Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
Description: Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
Description: Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
Description: Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
Description: Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
Description: Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule
Study: NCT05602675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3871801
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3871801
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally.
Study: NCT05616819

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active light exposure
Description: Active light at the wave length of 470nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a method to regulated circadian rhythm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light exposure
Description: Placebo light at the wave length of 578nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a control to investigate the regulation of circadian rhythm.
Study: NCT06366867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VibrantMinds
Description: VibrantMindVibrantMinds offers five tablet games targeting cognitive stimulation in older adults: Whack-A-Mole, Word Search, Bejeweled, Mahjong Solitaire, Memory Game, and Glenrose Grocery Game (GGG). These games vary from nostalgic (e.g., Mahjong Solitaire) to leisure-oriented (e.g., Bejeweled), aiming to blend fun with cognitive exercises. Especially designed for ease of use, they cater to older individuals, including those with dementia, gradually increasing in difficulty to match player skill levels. The GGG stands out by integrating game design with everyday cognitive tasks, offering a practical simulation of grocery shopping. Developed with older adult input, VibrantMinds aims to enhance cognitive health in seniors through engaging, meaningful gameplay, supporting its clinical trial's focus on cognitive wellness in the aging.
Study: NCT05403892

Intervention type: DIAGNOSTIC_TEST
Intervention: level laser lunge test
Description: In order to perform the Level Laser Test, the operator 1 places a laser lever on the ground one metre aside and 50 cm forward the ankle to be examined. This laser (a 2-class laser not harmful to the eyes) maintains a linear laser light beam perpendicular to the floor. The examined leg is placed further forward to the other one, as it happens in the DLT. The teenage performs a forward lunge perpendicularly to the laser line, the heel positioning 50 cm from the laser line. Operator 1 has the subject perform a lunge while operator 2 measures the distance from the kneecap to the laser line. The measurement, deducted by 50 cm, leads to the heel-to-wall distance (value used to DLT).
Study: NCT03895567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
Description: Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
Description: Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
Description: Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
Description: Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet
Study: NCT05403892

Intervention type: DIAGNOSTIC_TEST
Intervention: dorsiflexion Lunge test
Description: The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the teenage stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The teenage is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The teenage steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
Study: NCT06223789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation
Description: Pulsed field ablation using the Volt PFA System
Study: NCT04854889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Demethylating agents
Study: NCT06606587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort-in Jet Injection Method
Description: Application of Comfort-in Jet Injection Method: Comfort-in jet injection method was used for palatal anesthesia of the permanent 1st molar.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Dental Injection
Description: Application of Traditional Dental Injection Method: Traditional Dental Injection method was used for palatal anesthesia of the permanent 1st molar.
Study: NCT06607159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of healthy habits teaching protocol
Description: Protocol for teaching healthy lifestyle habits, aimed at school-age children (initially between 1st and 4th grade of primary school), to be implemented transversally in schools. This protocol takes into account three levels of action: school, family and pupils. It includes materials in paper format and digital materials, that can be used both at school and at home.
Study: NCT06607926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha 1
Description: 4.8 mg subcutaneous injection twice weekly over 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200mg, IV, d1 of each 21-d cycle, four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg, IV, d1 of each 21-d cycle, four cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-doublet chemotherapy
Description: Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy
Description: Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.